Break Wave Lithotripsy appears safe and efficacious in urolithiasis
May 10th 2023"In summary, it was safe and effective. There [were] no serious adverse events...and the vast majority of patients received no anesthesia with very similar results to shock wave lithotripsy,” said Ben H. Chew, MD, MSc, FRCSC.
Darolutamide linked to lower discontinuation and progression rates in nmCRPC
May 3rd 2023Data from the retrospective DEAR study linked darolutamide to lower rates of discontinuation and progression to metastatic disease vs enzalutamide and apalutamide in patients with nonmetastatic castration-resistant prostate cancer.
Early stent removal following radical cystectomy does not increase risk of UTI, urine leak
May 2nd 2023"At our institution, we used a [quality improvement] protocol to first decrease overall antibiotic duration from the more standard 30 days, and then we further decreased it along with ureteral stent decrease,” says Jessica Wenzel, MD, MPH.
Apalutamide/ADT prolongs PSA PFS in biochemically relapsed prostate cancer
May 2nd 2023Adding apalutamide to ADT with or without abiraterone acetate/prednisone significantly prolonged PSA PFS in men with biochemically relapsed prostate cancer, according to extended follow-up from the phase 3 PRESTO study.